NEW YORK (GenomeWeb) – A new study suggests some cancers can jettison a large proportion of mutations recognized by the immune system as they become resistant to immune checkpoint blockade treatments targeting PD1 and/or CTLA4.
Registering provides access to this and other free content.
Already have an account?Login Now.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.
This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.
This webinar will provide an overview of an RNA-seq protocol that has been optimized to study small RNA species such as microRNAs.
This webinar will discuss a target enrichment workflow for high-confidence detection of variants.
This webinar will discuss RNA sequencing as an alternative to immunohistochemistry (IHC) in selecting patients for cancer immunotherapy.